Ina Kenji, Furuta Ryuichi, Kataoka Takae, Kayukawa Satoshi, Yoshida Takashi, Miwa Takaya, Yamamura Yoshitaka, Takeuchi Yuuki
Kenji Ina, Ryuichi Furuta, Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya 468-8520, Japan.
World J Clin Oncol. 2011 Oct 10;2(10):339-43. doi: 10.5306/wjco.v2.i10.339.
To examine whether administration of lentinan, purified β-1, 3-glucan, can prolong survival in advanced gastric cancer patients receiving S-1-based chemotherapy.
Since 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone.
Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001).
Chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer.
研究给予香菇多糖（一种纯化的β-1,3-葡聚糖）是否能延长接受基于S-1化疗的晚期胃癌患者的生存期。
自2004年起，78例转移性或复发性胃癌患者接受了基于S-1的化疗作为一线治疗。对接受香菇多糖化疗免疫疗法的患者组和单纯化疗的患者组在生存期、副作用以及粒细胞/淋巴细胞比例（G/L比值）方面进行了比较。
前一组的中位总生存期显著长于后一组[689天（95%CI：431 - 2339天）对565天（95%CI：323 - 662天），P = 0.0406]。此外，接受香菇多糖治疗的患者的G/L比值维持在2或以下，显著低于单纯接受化疗的患者（P < 0.001）。
在晚期胃癌患者的生存期方面，香菇多糖化疗免疫疗法相较于单纯基于S-1的化疗具有显著优势。
